Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Net Income (2016 - 2025)

Dexcom (DXCM) has disclosed Net Income for 16 consecutive years, with $267.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 76.2% to $267.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $836.3 million, a 45.14% increase, with the full-year FY2025 number at $836.3 million, up 45.14% from a year prior.
  • Net Income was $267.3 million for Q4 2025 at Dexcom, down from $283.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $283.8 million in Q3 2025 to a low of $48.6 million in Q1 2023.
  • A 5-year average of $128.9 million and a median of $110.6 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: tumbled 86.26% in 2021, then surged 201.23% in 2024.
  • Dexcom's Net Income stood at $56.5 million in 2021, then surged by 62.48% to $91.8 million in 2022, then soared by 179.19% to $256.3 million in 2023, then crashed by 40.81% to $151.7 million in 2024, then surged by 76.2% to $267.3 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Net Income are $267.3 million (Q4 2025), $283.8 million (Q3 2025), and $179.8 million (Q2 2025).